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Background: Human ß-defensins are a family of antimicrobial peptides located at the mucosal surface. Both
sequence multi-site variations (MSV) and copy-number variants (CNV) of the defensin-encoding genes are
associated with increased risk for various diseases, including cancer and inflammatory conditions such as psoriasis
and acute pancreatitis. In a case–control study, we investigated the association between MSV in DEFB104 as well as
defensin gene (DEF) cluster copy number (CN), and pancreatic ductal adenocarcinoma (PDAC) and chronic
pancreatitis (CP).
Results: Two groups of PDAC (N=70) and CP (N=60) patients were compared to matched healthy control groups
CARLA1 (N=232) and CARLA2 (N=160), respectively. Four DEFB104 MSV were haplotyped by PCR, cloning and
sequencing. DEF cluster CN was determined by multiplex ligation-dependent probe amplification.
Neither the PDAC nor the CP cohorts show significant differences in the DEFB104 haplotype distribution compared
to the respective control groups CARLA1 and CARLA2, respectively.
The diploid DEF cluster CN exhibit a significantly different distribution between PDAC and CARLA1 (Fisher’s exact
test P=0.027), but not between CP and CARLA2 (P=0.867).
Conclusion: Different DEF cluster b CN distribution between PDAC patients and healthy controls indicate a
potential protective effect of higher CNs against the disease.
Keywords: Defensins, Single nucleotide variants, Copy number variation, Chronic pancreatitis, Pancreatic ductal
adenocarcinomaBackground
Pancreatitis, a necroinflammatory condition of the pan-
creas, has both acute and chronic manifestations. In the
recent past, our understanding of the pathogenesis of pan-
creatic inflammation has improved considerably. Whereas
acute pancreatitis is known to be initiated by premature
activation of digestive enzymes within the exocrine com-
ponent of the pancreas, chronic pancreatitis (CP) is char-
acterized by progressive and irreversible damage to both* Correspondence: stau@fli-leibniz.de
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CP is believed to result from repeated overt or silent epi-
sodes of acute pancreatitis [1]. The key histopathologic
features of CP are pancreatic fibrosis, acinar atrophy,
chronic inflammation, and distorted and blocked ducts
[2]. The annual incidence of CP in industrialized countries
ranges from 3.5 to 10 per 100,000. Alcohol abuse is the
major risk factor for CP in Western countries, although
other mechanisms such as mutations, pancreatic duct ob-
struction (caused by strictures), hypertriglyceridemia,
hypercalcemia, and autoimmunity also have been impli-
cated [3]. Since patients with CP have an approximately
13-fold higher risk to develop pancreatic cancer than the
general population, the identification of disease-relatedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from benign to malignant disorder, and for developing
strategies for early diagnosis [4]. Pancreatic cancer (pan-
creatic ductal adenocarcinoma, PDAC), is the fourth most
common cause of cancer-related death in industrialized
countries and characterized by extremely low survival
rates [5,6]. Currently, no imaging procedure can reliably
differentiate between benign and malignant tumors in CP
patients.
Defensins are small cysteine-rich peptides that can be
classified as either α-defensin or β-defensin, depending
upon the arrangement of six critical cysteine residues.
Defensins are synthesized as inactive preproproteins
that become post-translationally activated. They are
produced in the respiratory, gastrointestinal and geni-
tourinary tracts, the skin, and by circulating blood
cells. Defensins are considered a first line of defence
against invading pathogens. Of all defensins, the ß-
defensins comprise the largest group, with around 40
members encoded in the human genome. Most of the
genes are located in defensin (DEF) clusters on chro-
mosomes 8 and 20. In addition to their antimicrobial
activity, β-defensins have multifaceted functions in in-
nate and adaptive immunity [7]. The β-defensins are
expressed in most epithelial cells and are found to be
impaired in many inflammatory diseases, including
Crohn's disease, psoriasis, pulmonary inflammation,
and periodontal disease [8-13].
Except for DEFB1, all ß-defensin genes (DEFB4,
DEFB103-109) harbour a high degree of copy-number
variation (CNV). Copy numbers (CN) range from 2 to
13 copies per diploid genome and show large inter-genic
concordance because the respective genes bunch in aFigure 1 Genomic organization of the human defensin (DEF) gene clu
copy, except a CNV region encompassing DEFA1A3 and DEFT1p (2 to 13 co
CN-variable (2 to 12 copies). Black triangle (zoomed): DEFB104 gene with th
α-defensin; B: DEFB, ß-defensin; ex = exon, p = pseudogene.~200 kb CNV region, called ‘DEF cluster b’ (Figure 1)
[14-20]. In principle, both CNV and sequence variation
within a given copy can contribute to clinical phenotypes
through variation in gene expression [21]. So far, this
has only been demonstrated experimentally for DEFB4
but most probably applies to all other DEF genes with
variable CN as well [17]. Anyhow, the analysis of genes
located in CNV regions poses two methodological chal-
lenges: First, conventional genotyping of single nucleo-
tide variations (SNV) cannot resolve whether a variation
occurs between paralogs affected by CNV [22]. To ac-
knowledge this problem, we will address SNVs within
the copy number variable DEFB cluster as ‘multi-site
variation’ (MSV). Second, the assessment of CNs is also
complicated by methodological difficulties. Although
widely used, qPCR has questionable reliability so that
tightly controlled paralog ratio tests or multiplex
ligation-dependent probe amplification (MLPA) have
been recommended instead [23-28].
Disease association studies of the CN-variable ß-defen-
sin genes are scarce. Hitherto reported associations
mostly either lack replication or are conflicting [21,29-
32]. No CN association, but a skewed distribution of
MSV haplotypes, was identified in two prostate cancer
groups [33]. The corresponding haplotypes comprise
four MSV (rs17843871, rs2680507, rs17843872 and
rs4259430) around exon 1 of DEFB104. While haplo-
types GGGC and CAAT were significantly under-
represented among patients, GAAT and GAAC were sig-
nificantly over-represented. Moreover, high CNs of the
ß-defensin cluster (≥9 copies per diploid genome) were
found to be less frequent among prostate cancer patients
than among healthy controls.sters on chromosome 8p23.1. DEF cluster a is essentially single-
pies per diploid genome), whereas DEF cluster b as a whole is
e four multi site variations (MSV) investigated in this study. A: DEFA,
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tions between MSV-based DEFB104 haplotypes and DEF
cluster b CNs on the one hand, and pancreatic ductal
adenocarcinoma and chronic pancreatitis on the other.Results
DEFB104 haplotypes are not associated with PDAC or CP
Two independent cohorts of patients with pancreatic
ductal adenocarcinoma (PDAC) and chronic pancreatitis
(CP) were investigated in comparison with complemen-
tary age- and sex-matched healthy control groups [34]
named CARLA1 and CARLA2, respectively (Table 1 and
Methods section).
The haplotypes of four exon 1 MSV in DEFB104
(Figure 1) were determined by PCR on the genomic
DNAs from the four cohorts as well as from a com-
mercially available pool of ~100 anonymous human
DNAs. The PCR products were pooled by cohorts in
equimolar amounts and cloned. Subsequently, clones
were sequenced, haplotypes were inferred from the se-
quence traces and the haplotype fractions within cohorts
were calculated (Table 2). Since these fractions do not
take into account the effects of post-PCR pooling, how-
ever, they cannot be compared directly between patients
and controls using standard statistical tests. Instead, the
expected haplotype distribution under the null hypoth-
esis had to be simulated as previously described [33].
An omnibus χ2 test based upon these simulations yielded
a p value of 0.239 for the comparison of PDAC and
CARLA1, and of 0.129 for CP and CARLA2, respectively,
suggesting that there were no significant differences
between the DEFB104 haplotype distributions among
cases and controls.
DEF cluster b CN distribution differs between PDAC and
controls
Diploid DEF cluster b CNs were determined by MLPA for
65, 232, 63 and 161 individuals from the PDAC, CARLA1,
CP and CARLA2 groups, respectively (Additional files 1, 2,
3, 4 and 5). The median CN was 4 copies per diploidTable 1 Description of study groups
Group PDAC CARLA1 CP CARLA2
Number (%) male 37 (53%) 123 (53%) 49 (82%) 133 (83%)
female 33 (47%) 109 (47%) 11 (18%) 27 (17%)
total 70 232 60 160
Age (years) minimum 41 46 36 45
maximum 77 77 74 74
mean 63.8 65.0 50.2 52.5
median 67.0 66.8 49.0 50.0
PDAC: pancreatic ductal adenocarcinoma; CP: chronic pancreatitis; CARLA1,
CARLA2: healthy control groups which were age- and sex-matched to PDAC
and CP, respectively.genome for all groups. CNs ranged from 2 to 7 in the
PDAC group (mean: 4.22) and from 3 to 7 in the CP group
(mean: 4.57). In both control groups, CNs were between 2
and 8 copies (mean CARLA1: 4.42, CARLA2: 4.55).
Differences in mean CN between cases and control
groups were not statistically significant (PDAC vs
CARLA1: 0.20, P=0.151; CP vs CARLA2: 0.02, P=0.915)
(Additional file 6).
The diploid CN distributions within the four cohorts
are depicted in Figure 2. Application of Fisher’s exact
test revealed that these distributions differed significantly
between PDAC and CARLA1 (P=0.027), but not be-
tween CP and CARLA2 (P=0.867). The two control
groups also did not differ significantly from each other
(P=0.580).
Discussion
Defensins are expressed in the pancreas although it is
not entirely clear which cells actually produce and se-
crete which of these diverse peptides for which purpose.
In pancreatic juice, only HNP-3 (α-defensin 3, encoded
by DEFA3) has been detected but mRNA expression of
ß-defensins has also been demonstrated in pancreatic
tissue [35]. The important role of defensins in the innate
immune system due to their antimicrobial, chemotactic
and regulatory functions, and their involvement in in-
flammatory processes vindicates the assumption that
defensins are also involved in the pathogenesis of pan-
creatitis and pancreatic cancer.
Pancreatitis may develop as a chronic disease after
long-term alcohol abuse. Chronic pancreatitis is a strong
risk factor for pancreatic cancer but alcohol does not ap-
pear to be an independent causative agent for the dis-
ease [36,37]. Interestingly, acute and chronic pancreatic
inflammation occurs as an extra-intestinal co-morbidity
of inflammatory bowel disease for which an involvement
of defensins is also discussed [27,38,39]. Furthermore, in
view of the microbicidal properties of defensins, it
appears noteworthy that a link between infectious dis-
eases and pancreatic cancer has been drawn both for
viral diseases (mumps, HBV infections) and bacterial
infections (Helicobacter pylori) [37,40].
In the present study, both sequence variants in a ß-
defensin gene and CN variants of the cluster containing
this gene were investigated for a putative association
with PDAC and CP. As haplotyping of the CN-variable
DEFB104 gene was performed in pools, haplotypes can-
not be assigned to the individual diploid CN for DEF
cluster b. Respectively, both features had to be tested for
association independently. All data from the patient
groups were compared to age- and sex-matched healthy
controls (CARLA1 and CARLA2).
Earlier, we have demonstrated association between
DEFB104 haplotypes and sporadic prostate cancer as
Table 2 Haplotype frequencies (fh) as derived for DEFB104 MSV rs17843871, rs2680507, rs17843872 and rs4259430 by
pooled PCR/cloning and Sanger sequencing
Haplotype Frequency as determined by pooled PCR/sequencing Group comparison
PDAC CARLA1 CP CARLA2 Human genomic
pool
PDAC vs CARLA1 CP vs CARLA2
No. clones fh No. clones fh No. clones fh No. clones fh No. clones fh P* P*
GAGC 224 0.40 286 0.34 310 0.41 391 0.34 413 0.38 0.160 0.061
GGGC 152 0.27 207 0.25 200 0.27 277 0.24 233 0.21 0.540 0.444
GAAT 39 0.07 92 0.11 92 0.12 153 0.13 106 0.10 0.109 0.747
CAGT 60 0.11 65 0.08 63 0.08 91 0.08 62 0.06 0.232 0.813
CAAT 29 0.05 48 0.06 27 0.04 76 0.07 47 0.04 0.773 0.123
CAGC 15 0.03 36 0.04 23 0.03 56 0.05 59 0.05 0.316 0.298
GAGT 22 0.04 28 0.03 9 0.01 41 0.04 54 0.05 0.721 0.079
GAAC 5 0.01 22 0.03 7 0.01 28 0.02 12 0.01 0.136 0.194
GGAT 3 0.01 22 0.03 2 <0.01 14 0.01 27 0.02 0.059 0.217
GGGT 7 0.01 10 0.01 2 <0.01 9 0.01 25 0.02 0.961 0.430
CGGC 6 0.01 5 0.01 2 <0.01 12 0.01 22 0.02 0.547 0.297
CGGT 0 0.00 5 0.01 1 <0.01 3 <0.01 0 0.00 0.163 0.720
GGAC 0 0.00 4 <0.01 0 0.00 0 0.00 6 0.01 0.222 n.a.
CAAC 1 <0.01 2 <0.01 0 0.00 2 <0.01 0 0.00 0.781 0.318
CGAT 1 <0.01 2 <0.01 0 0.00 0 0.00 4 <0.01 0.783 n.a
Total 564 834 738 1.153 1.070 0.239 0.129
* P values for the comparison of case and control haplotype frequencies were based upon simulations as previously described [33].
Taudien et al. BMC Research Notes 2012, 5:629 Page 4 of 8
http://www.biomedcentral.com/1756-0500/5/629well as under-representation of high diploid DEF cluster
CN in patients with this disease [33]. In the present
study, no statistical support was found for an association
between DEFB104 haplotypes and either PDAC or CP.
However, analysis of the diploid CN distributions
revealed a statistically significant difference between
PDAC and CARLA1 that was due mainly to a paucity of
5- and 6-copy samples and an excess of 3-copy ones in
the PDAC cohort.
Recently, under-representation of higher diploid DEFB4
CNs (>4) was reported in patients with acute pancreatitis
(AP) and severe acute pancreatitis (SAP) [41]. Since
DEFB4 is part of DEF cluster b and concordance for the
CN of all genes within cluster b has been shown [16], this
result is in agreement with our findings in the PDAC co-
hort. However, for CP, known to increase the risk for
developing pancreatic cancer by 10 to 20-fold and a pos-
sible outcome of AP, we and others [42] did not observe
significant associations with genetic features of the DEF
cluster b, potentially pinpointing different roles of defen-
sins in the etiopathogenesis of pancreatic diseases.
Although the functional consequences of the lower DEF
cluster b CN observed for PDAC and AP are not yet
resolved, lower CNs are rather associated with lower
defensin expression [17]. In the light of inflammation as
key feature of AP and the established link between inflam-
mation and cancer [43], a low CN would be consistentwith an anti-inflammatory effect of defensins described re-
cently [44]. Assuming instead defensins to exert a pro-
inflammatory effect [45] would favor a role of perturbed
antimicrobial barrier defense in the etiopathogenesis of
PDAC and AP. Further studies are necessary to find these
missing functional links and to clarify which genetic var-
iants may serve as reliable and feasible markers in the
diagnosis and prognosis of pancreatic diseases.
Conclusion
Different DEF cluster b CN distribution between PDAC
patients and healthy controls indicate a potential pro-
tective effect of higher CNs against the disease. Replica-
tion of the study with larger sample numbers are needed
to confirm the result and to draw definitive conclusions
thereof.
Methods
Patients, DNA samples and Oligonucleotides
All individuals were of European origin. Cases of PDAC
and CP were taken from two cohorts of patients with
PDAC and CP who previously had undergone pylorus-
preserving pancreatico-duodenectomy. They were com-
plemented by age- and sex-matched healthy control
groups sampled from the CARLA Study, a prospective
cohort study of the general elderly population [34]. The
sampled controls from CARLA were free from heart
Figure 2 Distribution of DEF cluster b CN per diploid genome in the PDAC and CARLA1 (top) and CP and CARLA2 (bottom) cohorts.
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without intake of antiphlogistic medication (Anatomical
Therapeutic Chemical Classification System (ATC) code
A07). A description of the age- and sex-distribution of
the groups is given in Table 1.
Genomic DNA was obtained from peripheral blood
collected in EDTA tubes (QIAamp DNA Mini Kit). The
studies were approved by the ethics committees of the
Universities of Dresden (Vote No. EK96042007) andHalle (Vote No. 1983-01/07). Written informed consent
was obtained from all participants. The funding sources
of the study played no role in the study design, data col-
lection, data analysis, data interpretation or writing of
the report. A human genomic DNA pool derived from
~100 anonymous individuals (Roche Diagnostics, Cat.
No. 1691112) served as an additional control. All pri-
mers were synthesized by Metabion AG (Martinsried,
Germany).
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Amplification from individual genomic DNAs was car-
ried out using primers 5'-TTCTGTAGCCCCAA
CACCTC-3' and 5'-GGTGCCAAGGACATCTAGGA-3',
resulting in a 500 bp PCR product spanning four MSV
(rs17843871, rs2680507, rs17843872, rs4259430) around
exon 1 of DEFB104 (GenBank Refseq NM_080389.2).
PCR reactions were performed as described with the fol-
lowing cycling conditions: 95°C for 1 min; 5 cycles at
95°C for 30 s, 56°C for 30 s, and 72°C for 60 s, 27 cycles
at 95°C for 30 s, 58°C for 30 s, and 72°C for 60 s, with a
final extension at 72°C for 5 min [33]. The concentra-
tions of PCR products were measured by use of a
Nanodrop device and equal amounts were pooled per
cohort. Pooled DNAs were cloned into pCR2.1-TOPO
(Invitrogen) according to the manufacturer’s instruc-
tions and transformed into E.coli by electroporation.
Well-isolated colonies were transferred and grown in
LB broth supplemented with ampicillin. Plasmid DNA
was isolated from the cultures by BioRobot 8000 and
MagAttract 96 Miniprep Core Kit (Qiagen) and inserts
were sequenced in both directions using M13 universal
primers. Haplotypes were called by visual inspection of
the sequence traces.
DEF cluster copy numbers
For all individuals of the PDAC, CP, CARLA1 and
CARLA2 cohorts, CNs of DEF cluster b (including
DEFB104, Figure 1) were determined by multiplex
ligation-dependent probe amplification (MLPA), using
the P139 kit (MRC Holland), as previously described
[16]. The MLPA probe set consists of 43 probes of
which 10 are hybridizing to genes/pseudogenes within
DEF cluster a, 10 to genes within DEF cluster b and 23
to bona fide single-copy genes flanking the defensin
clusters as well as on other chromosomes, respectively.
Peak areas were normalized against the summed peak
areas of the “five nearest neighbor” (5nn) reference
probes for each individual sample, relative locus doses
were calculated and the diploid copy numbers were in-
ferred. As internal quality control, four DNAs
(NA18552, NA15324, NA12760, NA18858) with known
CN (2, 4, 6 and 8, respectively) from commercially avail-
able lymphoblastoid cell lines (Coriell Cell repository
http://www.coriell.org/) were used as copy number stan-
dards. Reliable copy number details from these samples
are from independent, methodologically different deter-
minations from different laboratories (see Table 2 in
Groth et al. 2008 and references therein).
Statistics
Following our PCR and sequencing approach, DEFB104
haplotype determination is hampered by the fact that
post-PCR pooling leads to an over-representation ofalleles derived from individuals with low DEF cluster CN
whilst alleles from genomes with high CN are under-
represented. Furthermore, the number of sequenced
clones differed considerably between the groups, ranging
from 564 to 1153. This implies that haplotypes as called
from sequence traces do not represent statistically inde-
pendent observations and do not reflect the truly under-
lying haplotype distribution. Therefore, a haplotype-wise
χ2 test could not be applied in the case–control compar-
isons. Instead, we simulated genotypes with respect to
individual CN under the null hypothesis (i.e. no differ-
ence between cases and controls) and derived reference
haplotype distributions for statistical testing from these
simulated data, as previously described [33].
Differences in DEF cluster b CNs between cases and
controls were first assessed by a comparison of the
group-specific mean diploid CNs. Since the mean may
not be a sufficient statistic for the underlying genotype
distribution, diploid CN was also treated as a qualitative
variable and gauged for statistically significant differ-
ences between groups using Fisher’s exact test as imple-
mented in the SAS statistical analysis package V9.2 (SAS
Inc., Cary, NY).
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genome determined by MLPA, PDAC cohort.
Additional file 2: Integer DEF cluster b copy numbers per diploid
genome determined by MLPA, CP cohort.
Additional file 3: Integer DEF cluster b copy numbers per diploid
genome determined by MLPA, CARLA1 cohort.
Additional file 4: Integer DEF cluster b copy numbers per diploid
genome determined by MLPA, CARLA2 cohort.
Additional file 5: Summary of DEF cluster b CN distribution.
Additional file 6: Statistics for comparisons of DEF cluster b CN
distribution.
Competing interests
The authors declare that they have no competing interests.
Author’s contributions
GG, CP and RG collected the disease cohort’s samples and provided the
patient’s data. KHG, KW, AK and OK conceived the CARLA study, did the
cohort matching and provided the control samples. They also performed the
statistical analyses with the support of MK, AW and MN. ST and MG carried
out the molecular genetic studies with support by PR. ST, KH and MP drafted
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank Ivonne Heinze, Ivonne Görlich, Kathleen Seitz, Beate Szafranski and
Daniela Werler (FLI Jena) for skilful technical assistance. The PDAC and CP
studies were financially supported by grants from the Bundesministerium für
Bildung und Forschung for the National Genome Research Network of
Environmental Disorders (01GS0809), the Deutsche Forschungsgemeinschaft
(DFG) and from the Technical University of Dresden (“MedDrive der
Medizinischen Fakultät Dresden”). The CARLA study was funded by a DFG
grant as part of the Collaborative Research Center 598 “Heart failure in the
elderly – cellular mechanisms and therapy” at the Medical Faculty of the
Martin Luther University Halle-Wittenberg; by a grant of the Wilhelm Roux
Taudien et al. BMC Research Notes 2012, 5:629 Page 7 of 8
http://www.biomedcentral.com/1756-0500/5/629Programme of the Martin Luther University Halle-Wittenberg; and by the
Federal Employment Office.
Author details
1Genome Analysis, Leibniz Institute for Age Research - Fritz Lipmann
Institute, Beutenbergstr 11, D-07745 Jena, Germany. 2Department of Visceral,
Thoracic and Vascular Surgery, University Hospital, Technical University of
Dresden, Dresden, Germany. 3Institute for Medical Epidemiology, Biostatistics
and Informatics, Martin Luther University Halle-Wittenberg, Halle (Saale),
Germany. 4Institute for Medical Informatics and Statistics, Christian Albrechts
University Kiel, Kiel, Germany. 5Institute for Clinical Molecular Biology,
Christian Albrechts University Kiel, Kiel, Germany. 6German Cancer Research
Centre, Division of Cancer Epidemiology, Heidelberg, Germany. 7Department
of Medicine III, Martin Luther University Halle-Wittenberg, Halle (Saale),
Germany. 8Cologne Center for Genomics, University of Cologne, Cologne,
Germany.
Received: 29 June 2012 Accepted: 7 November 2012
Published: 13 November 2012References
1. Skipworth JR, Shankar A, Pereira SP: Managing acute and chronic
pancreatitis. Practitioner 2010, 254:23–27. 22.
2. Kloppel G, Maillet B: Development of chronic pancreatitis from acute
pancreatitis: a pathogenetic concept. Zentralbl Chir 1995, 120:274–277.
3. Ahmed SA, Wray C, Rilo HL, Choe KA, Gelrud A, Howington JA, Lowy AM,
Matthews JB: Chronic pancreatitis: recent advances and ongoing
challenges. Curr Probl Surg 2006, 43:127–238.
4. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R:
Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early
detection. Best Pract Res Clin Gastroenterol 2010, 24:349–358.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
6. Raptis DA, Fessas C, Belasyse-Smith P, Kurzawinski TR: Clinical presentation
and waiting time targets do not affect prognosis in patients with
pancreatic cancer. Surgeon 2010, 8:239–246.
7. Lehrer RI: Immunology: Peptide gets in shape for self-defence. Nature
2011, 469:309–310.
8. Beisswenger C, Bals R: Antimicrobial peptides in lung inflammation. Chem
Immunol Allergy 2005, 86:55–71.
9. Diamond G, Ryan L: Beta-defensins: what are they REALLY doing in the
oral cavity? Oral Dis 2011, 17(7):628–635.
10. Guani-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Teran LM: Antimicrobial
peptides: general overview and clinical implications in human health
and disease. Clin Immunol 2010, 135:1–11.
11. Herr C, Shaykhiev R, Bals R: The role of cathelicidin and defensins in
pulmonary inflammatory diseases. Expert Opin Biol Ther 2007, 7:1449–1461.
12. Hollox EJ: Copy number variation of beta-defensins and relevance to
disease. Cytogenet Genome Res 2008, 123:148–155.
13. Paris S, Wolgin M, Kielbassa AM, Pries A, Zakrzewicz A: Gene expression of
human beta-defensins in healthy and inflamed human dental pulps.
J Endod 2009, 35:520–523.
14. Hollox EJ, Armour JA, Barber JC: Extensive normal copy number variation
of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet 2003,
73:591–600.
15. Taudien S, Galgoczy P, Huse K, Reichwald K, Schilhabel M, Szafranski K,
Shimizu A, Asakawa S, Frankish A, Loncarevic IF, et al: Polymorphic
segmental duplications at 8p23.1 challenge the determination of
individual defensin gene repertoires and the assembly of a contiguous
human reference sequence. BMC Genomics 2004, 5:92.
16. Groth M, Szafranski K, Taudien S, Huse K, Mueller O, Rosenstiel P, Nygren
AO, Schreiber S, Birkenmeier G, Platzer M: High-resolution mapping of the
8p23.1 beta-defensin cluster reveals strictly concordant copy number
variation of all genes. Hum Mutat 2008, 29:1247–1254.
17. Groth M, Wiegand C, Szafranski K, Huse K, Kramer M, Rosenstiel P, Schreiber
S, Norgauer J, Platzer M: Both copy number and sequence variations
affect expression of human DEFB4. Genes Immun 2010, 11:458–466.
18. Hardwick RJ, Machado LR, Zuccherato LW, Antolinos S, Xue Y, Shawa N,
Gilman RH, Cabrera L, Berg DE, Tyler-Smith C, et al: A worldwide analysis of
beta-defensin copy number variation suggests recent selection of ahigh-expressing DEFB103 gene copy in East Asia. Hum Mutat 2011,
32:743–750.
19. Taudien S, Groth M, Huse K, Petzold A, Szafranski K, Hampe J, Rosenstiel P,
Schreiber S, Platzer M: Haplotyping and copy number estimation of the
highly polymorphic human beta-defensin locus on 8p23 by 454
amplicon sequencing. BMC Genomics 2010, 11:252.
20. Taudien S, Szafranski K, Felder M, Groth M, Huse K, Raffaelli F, Petzold A, Zhang
X, Rosenstiel P, Hampe J, et al: Comprehensive assessment of sequence
variation within the copy number variable defensin cluster on 8p23 by
target enriched in-depth 454 sequencing. BMC Genomics 2011, 12:243.
21. Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-Olthuis D, van
de Kerkhof PC, Traupe H, de Jongh G, den Heijer M, et al: Psoriasis is
associated with increased beta-defensin genomic copy number. Nat
Genet 2008, 40:23–25.
22. Fredman D, White SJ, Potter S, Eichler EE, Den Dunnen JT, Brookes AJ:
Complex SNP-related sequence variation in segmental genome
duplications. Nat Genet 2004, 36:861–866.
23. Armour JA, Palla R, Zeeuwen PL, den Heijer M, Schalkwijk J, Hollox EJ:
Accurate, high-throughput typing of copy number variation using
paralogue ratios from dispersed repeats. Nucleic Acids Res 2007, 35:e19.
24. Deutsch S, Choudhury U, Merla G, Howald C, Sylvan A, Antonarakis SE:
Detection of aneuploidies by paralogous sequence quantification. J Med
Genet 2004, 41:908–915.
25. Lee HH, Chang JG, Lin SP, Chao HT, Yang ML, Ng HT: Rapid detection of
trisomy 21 by homologous gene quantitative PCR (HGQ-PCR). Hum Genet
1997, 99:364–367.
26. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G:
Relative quantification of 40 nucleic acid sequences by multiplex
ligation-dependent probe amplification. Nucleic Acids Res 2002, 30:e57.
27. Aldhous MC, Abu Bakar S, Prescott NJ, Palla R, Soo K, Mansfield JC, Mathew
CG, Satsangi J, Armour JA: Measurement methods and accuracy in copy
number variation: failure to replicate associations of beta-defensin copy
number with Crohn's disease. Hum Mol Genet 2010, 19:4930–4938.
28. Perne A, Zhang X, Lehmann L, Groth M, Stuber F, Book M: Comparison of
multiplex ligation-dependent probe amplification and real-time PCR
accuracy for gene copy number quantification using the beta-defensin
locus. Biotechniques 2009, 47:1023–1028.
29. Chen Q, Hakimi M, Wu S, Jin Y, Cheng B, Wang H, Xie G, Ganz T, Linzmeier
RM, Fang X: Increased genomic copy number of DEFA1/DEFA3 is
associated with susceptibility to severe sepsis in Chinese Han
population. Anesthesiology 2010, 112:1428–1434.
30. Aldhous MC, Noble CL, Satsangi J: Dysregulation of human beta-defensin-
2 protein in inflammatory bowel disease. PLoS One 2009, 4:e6285.
31. Bentley RW, Pearson J, Gearry RB, Barclay ML, McKinney C, Merriman TR,
Roberts RL: Association of Higher DEFB4 Genomic Copy Number With
Crohn's Disease. Am J Gastroenterol 2009, 105(2):354–359.
32. Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, Bevins CL,
Reinisch W, Teml A, Schwab M, Lichter P, et al: A chromosome 8 gene-
cluster polymorphism with low human beta-defensin 2 gene copy
number predisposes to Crohn disease of the colon. Am J Hum Genet
2006, 79:439–448.
33. Huse K, Taudien S, Groth M, Rosenstiel P, Szafranski K, Hiller M, Hampe J,
Junker K, Schubert J, Schreiber S, et al: Genetic variants of the copy
number polymorphic beta-defensin locus are associated with sporadic
prostate cancer. Tumour Biol 2008, 29:83–92.
34. Greiser KH, Kluttig A, Schumann B, Kors JA, Swenne CA, Kuss O, Werdan K,
Haerting J: Cardiovascular disease, risk factors and heart rate variability in
the elderly general population: design and objectives of the
CARdiovascular disease, Living and Ageing in Halle (CARLA) Study. BMC
Cardiovasc Disord 2005, 5:33.
35. Gronborg M, Bunkenborg J, Kristiansen TZ, Jensen ON, Yeo CJ, Hruban RH,
Maitra A, Goggins MG, Pandey A: Comprehensive proteomic analysis of
human pancreatic juice. J Proteome Res 2004, 3:1042–1055.
36. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG,
Andersen JR, Dimagno EP, Andren-Sandberg A, Domellof L: Pancreatitis
and the risk of pancreatic cancer. International Pancreatitis Study Group.
N Engl J Med 1993, 328:1433–1437.
37. Raimondi S, Maisonneuve P, Lowenfels AB: Epidemiology of pancreatic
cancer: an overview. Nat Rev Gastroenterol Hepatol 2009, 6:699–708.
38. Pitchumoni CS, Rubin A, Das K: Pancreatitis in inflammatory bowel
diseases. J Clin Gastroenterol 2010, 44:246–253.
Taudien et al. BMC Research Notes 2012, 5:629 Page 8 of 8
http://www.biomedcentral.com/1756-0500/5/62939. Hollox EJ: Beta-defensins and Crohn's disease: confusion from counting
copies. Am J Gastroenterol 2010, 105:360–362.
40. Jerrells TR, Vidlak D, Strachota JM: Alcoholic pancreatitis: mechanisms of
viral infections as cofactors in the development of acute and chronic
pancreatitis and fibrosis. J Leukoc Biol 2007, 81:430–439.
41. Tiszlavicz Z, Szabolcs A, Takacs T, Farkas G, Kovacs-Nagy R, Szantai E, Sasvari-
Szekely M, Mandi Y: Polymorphisms of beta defensins are associated with
the risk of severe acute pancreatitis. Pancreatology 2010, 10:483–490.
42. Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W, Mark Evers B:
Inflammatory mechanisms contributing to pancreatic cancer
development. Ann Surg 2004, 239:763–769. discussion 769–771.
43. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002, 420:860–867.
44. Kohlgraf KG, Pingel LC, Dietrich DE, Brogden KA: Defensins as anti-
inflammatory compounds and mucosal adjuvants. Future Microbiol 2010,
5:99–113.
45. Ganz T: Defensins: antimicrobial peptides of innate immunity. Nat Rev
Immunol 2003, 3:710–720.
doi:10.1186/1756-0500-5-629
Cite this article as: Taudien et al.: Association studies of the copy-
number variable ß-defensin cluster on 8p23.1 in adenocarcinoma and
chronic pancreatitis. BMC Research Notes 2012 5:629.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
